Noile-Immune Biotech Inc.
4893・Growth Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. The Board of Directors consists of 5 members (including 2 outside directors, a 40% outside ratio), and all 3 corporate auditors are outside auditors. A Compensation Committee (chaired by an outside director) and a Conflict of Interest Committee have been established. The Board of Directors met 14 times during the fiscal year under review, with all officers attending every meeting. No Nomination Committee has been established.
Risk Management
The Company has established risk management regulations and holds a Risk Management Meeting, chaired by the Representative Director with each division head as a member, at least once every two months. The meeting identifies and evaluates new risks and determines response measures, and when risks materialize, investigates root causes and discusses countermeasures. Sustainability-related risks are managed in an integrated manner together with overall management risks.
Shareholder Returns
No dividends have been paid since the company's founding. The annual dividend is ¥0 for FY2025 (ending December 2025) and is forecast at ¥0 for FY2026 (ending December 2026) as well. The company's policy is to refrain from paying dividends for the time being in order to prioritize securing funds for upfront investment in R&D activities. No share buybacks or shareholder benefit programs are implemented.
Dividend Policy
The company has not paid dividends since its founding. The annual dividend for FY2025 (ending December 2025) is ¥0 (¥0 at the end of the second quarter, ¥0 at year-end), and the forecast annual dividend for FY2026 (ending December 2026) is also ¥0. For the time being, the company prioritizes securing funds to enable the continuous and planned implementation of R&D activities, and does not intend to pay dividends. In the future, the company will consider distributing surplus while taking into account its business performance and financial position. When dividends of surplus are paid, the basic policy is to pay a year-end dividend once a year, with the decision-making body being the general meeting of shareholders. The articles of incorporation stipulate that interim dividends may be implemented by resolution of the Board of Directors.
ESG
The company positions its business activities in line with SDG Goal 3 "Good Health and Well-Being," emphasizing its contribution to cancer treatment through CAR-T cell therapy. On the human capital front, it promotes the recruitment, development, and creation of a comfortable working environment for personnel with diverse nationalities and backgrounds (remote work system, advanced professional system, individualized development plans). However, quantitative targets for sustainability indicators have not yet been established; the company states it will proceed with data collection and analysis going forward and consider setting targets. There is no specific disclosure regarding climate change.
Last updated: March 23, 2026